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Introduction
VAP is the primary infection acquired in Intensive Care
Units (ICU). Our goal has been to decrease the state
average rate of VAP within 9 episodes per 1,000 days of
mechanical ventilation. for this, Spanish Society of
Intensive Care Medicine (SEMICYUC), has agreed mea-
sures called Pneumonia Zero (NZ) program
Objectives
We analyze the results before DDS, after DDS’ implan-
tation and after implantation NZ, and compare them
with the rest of the country.
Methods
- Data from the ENVIN registration: 01.01.05 /
01.01.15. ICU with 10 beds.
- We start DDS (in 2009) before the NZ program was
recommended by SEMICYUC.
- Import of DDS from a pharmacy which is performed
by master formulates.
- Conduct training and educational campaign (presen-
cial and by means of internet) to professionals of ICU
(total of 58 people).
- Mandatory measures for the prevention of VAP:
proper training in airway management, strict hand
hygiene, control of pneumopressure ball(> 20 cmH2O),
oral hygiene every 6-8 hours, avoid, whenever possible,
supine position at 0 °, reduce intubation and / or its
duration, prevent the programated change of tubing,
humidifiers and tracheal tubes
- Statistical Support ENVIN: Rate/100 patients
admitted, 100 days of stay (pDS), 100 patients mechani-
cal ventilation (pMV). N = 3388 pattients admitted.
Results
- BEFORE DDS: 01/01/05-31/01/09. N = 542. VAP 30.
5´54/100 pattients, 8´37/100 DS, 15´08/100 MV. Spain :
5´29/100 pattients, 7´35/100 DS.
- DDS: 01/01/09-31/01/11. N = 1163. VAP 6. 0´52/
100 pattients, 1´06/100 DS, 2´25/100 MV. Spain : 1´93/
100 pattients, 3´14/DS, 8´87/100 MV.
- NZ : 01/01/11-31/01/15. N = 1683, VAP 5. 0´3/100
pattients, 0´66/100 DS, 1´47/100 MV. Spain : 1´43/100
pattients, 2´77/100 DS, 5´8/100 MV.
Conclusions
Our numbers, compared to the rest of Spain, show a
lower incidence of VAP. After the application of DDS
and the establishment of NZ program, has drastically
reduced the incidence of VAP. There is hardly any dif-
ference between the rate of VAP obtained after starting
DDS and obtained by implanting NZ. We can say that
both stuck (DDS and NZ) are adequate to prevent VAP.
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